MX395722B - Terapia de combinación para enfermedad pulmonar obstructiva crónica (epoc). - Google Patents
Terapia de combinación para enfermedad pulmonar obstructiva crónica (epoc).Info
- Publication number
- MX395722B MX395722B MX2019001587A MX2019001587A MX395722B MX 395722 B MX395722 B MX 395722B MX 2019001587 A MX2019001587 A MX 2019001587A MX 2019001587 A MX2019001587 A MX 2019001587A MX 395722 B MX395722 B MX 395722B
- Authority
- MX
- Mexico
- Prior art keywords
- pulmonary disease
- chronic obstructive
- obstructive pulmonary
- copd
- combination therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/20—Valves specially adapted to medical respiratory devices
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16184608 | 2016-08-17 | ||
| PCT/EP2017/070850 WO2018033598A1 (en) | 2016-08-17 | 2017-08-17 | Combination therapy for copd |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019001587A MX2019001587A (es) | 2019-07-04 |
| MX395722B true MX395722B (es) | 2025-03-25 |
Family
ID=56740118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019001587A MX395722B (es) | 2016-08-17 | 2017-08-17 | Terapia de combinación para enfermedad pulmonar obstructiva crónica (epoc). |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US10098837B2 (enExample) |
| EP (1) | EP3500241B1 (enExample) |
| JP (1) | JP7384666B2 (enExample) |
| KR (1) | KR102440850B1 (enExample) |
| CN (1) | CN109562061A (enExample) |
| AU (1) | AU2017314153B2 (enExample) |
| BR (1) | BR112019003173A2 (enExample) |
| CA (1) | CA3029481A1 (enExample) |
| DK (1) | DK3500241T3 (enExample) |
| EA (1) | EA201990514A1 (enExample) |
| ES (1) | ES2961242T3 (enExample) |
| FI (1) | FI3500241T3 (enExample) |
| GE (2) | GEP20227418B (enExample) |
| HR (1) | HRP20231729T1 (enExample) |
| HU (1) | HUE064623T2 (enExample) |
| IL (1) | IL264612B2 (enExample) |
| LT (1) | LT3500241T (enExample) |
| MA (1) | MA45984B1 (enExample) |
| MD (1) | MD3500241T2 (enExample) |
| MX (1) | MX395722B (enExample) |
| NZ (1) | NZ750214A (enExample) |
| PH (1) | PH12019500315A1 (enExample) |
| PL (1) | PL3500241T3 (enExample) |
| PT (1) | PT3500241T (enExample) |
| RS (1) | RS64751B1 (enExample) |
| SG (1) | SG11201900471VA (enExample) |
| SI (1) | SI3500241T1 (enExample) |
| UA (1) | UA123231C2 (enExample) |
| WO (1) | WO2018033598A1 (enExample) |
| ZA (1) | ZA201900239B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060257324A1 (en) | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
| HRP20140582T4 (hr) * | 2009-12-23 | 2023-06-09 | Chiesi Farmaceutici S.P.A. | Kombinacijska terapija za copd |
| US10098837B2 (en) | 2016-07-28 | 2018-10-16 | Chiesi Farmaceutici S.P.A. | Combination therapy for COPD |
| CN112438966B (zh) * | 2019-08-30 | 2022-08-26 | 四川普锐特药业有限公司 | 一种医用定量吸入气雾剂 |
| PH12022551243A1 (en) * | 2019-12-02 | 2023-09-11 | Chiesi Farm Spa | Stainles steel can for pressurised metered dose inhalers |
| GB2593283B (en) * | 2020-01-28 | 2023-09-13 | Chiesi Farm Spa | Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation |
| US20230080276A1 (en) * | 2020-02-20 | 2023-03-16 | Chiesi Farmaceutici S.P.A. | Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation |
| EP4188327B1 (en) | 2020-07-31 | 2025-05-28 | Chemo Research, S.L. | Combination therapy for inhalation administration |
| EP4225267A1 (en) * | 2020-10-09 | 2023-08-16 | Chiesi Farmaceutici S.p.A. | A pharmaceutical formulation for pressurised metered dose inhaler |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| IT1317720B1 (it) | 2000-01-07 | 2003-07-15 | Chiesi Farma Spa | Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani. |
| GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| EE05167B1 (et) | 2000-05-22 | 2009-06-15 | Chiesi Farmaceutici S.P.A. | Stabiilsed farmatseutilised lahuspreparaadid survestatud doseerivatele inhalaatoritele |
| EP1321159A1 (en) | 2001-12-21 | 2003-06-25 | CHIESI FARMACEUTICI S.p.A. | Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices |
| ES2413011T3 (es) | 2004-02-06 | 2013-07-15 | Meda Pharma Gmbh & Co. Kg | Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC |
| GB0410399D0 (en) | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| EP2484382A1 (en) | 2005-03-30 | 2012-08-08 | Schering Corporation | Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form |
| GB0523653D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523656D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523654D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523655D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| HRP20140582T4 (hr) * | 2009-12-23 | 2023-06-09 | Chiesi Farmaceutici S.P.A. | Kombinacijska terapija za copd |
| WO2014033057A1 (en) | 2012-08-29 | 2014-03-06 | Chiesi Farmaceutici S.P.A. | Aerosol inhalation device |
| WO2014190204A1 (en) | 2013-05-22 | 2014-11-27 | Pearl Therapeutics, Inc. | Compositions, methods & systems for respiratory delivery of three or more active agents |
| JP6534397B2 (ja) * | 2013-12-30 | 2019-06-26 | シエシー ファルマセウティチィ ソシエタ ペル アチオニ | グリコピロニウム臭化物およびホルモテロールの組合せの安定な加圧エアゾール溶液組成物 |
| AU2014375301C1 (en) | 2013-12-30 | 2026-02-19 | Chiesi Farmaceutici S.P.A. | Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination |
| US10098837B2 (en) | 2016-07-28 | 2018-10-16 | Chiesi Farmaceutici S.P.A. | Combination therapy for COPD |
-
2017
- 2017-07-28 US US15/663,364 patent/US10098837B2/en active Active
- 2017-08-17 AU AU2017314153A patent/AU2017314153B2/en active Active
- 2017-08-17 GE GEAP201715023A patent/GEP20227418B/en unknown
- 2017-08-17 GE GEAP202215023A patent/GEAP202215023A/en unknown
- 2017-08-17 RS RS20231015A patent/RS64751B1/sr unknown
- 2017-08-17 HU HUE17758473A patent/HUE064623T2/hu unknown
- 2017-08-17 FI FIEP17758473.7T patent/FI3500241T3/fi active
- 2017-08-17 CA CA3029481A patent/CA3029481A1/en active Pending
- 2017-08-17 HR HRP20231729TT patent/HRP20231729T1/hr unknown
- 2017-08-17 MX MX2019001587A patent/MX395722B/es unknown
- 2017-08-17 JP JP2019530539A patent/JP7384666B2/ja active Active
- 2017-08-17 BR BR112019003173A patent/BR112019003173A2/pt unknown
- 2017-08-17 SI SI201731458T patent/SI3500241T1/sl unknown
- 2017-08-17 KR KR1020197004574A patent/KR102440850B1/ko active Active
- 2017-08-17 CN CN201780049986.3A patent/CN109562061A/zh active Pending
- 2017-08-17 ES ES17758473T patent/ES2961242T3/es active Active
- 2017-08-17 DK DK17758473.7T patent/DK3500241T3/da active
- 2017-08-17 EP EP17758473.7A patent/EP3500241B1/en active Active
- 2017-08-17 MA MA45984A patent/MA45984B1/fr unknown
- 2017-08-17 LT LTEPPCT/EP2017/070850T patent/LT3500241T/lt unknown
- 2017-08-17 PT PT177584737T patent/PT3500241T/pt unknown
- 2017-08-17 NZ NZ750214A patent/NZ750214A/en unknown
- 2017-08-17 UA UAA201902491A patent/UA123231C2/uk unknown
- 2017-08-17 MD MDE20190710T patent/MD3500241T2/ro unknown
- 2017-08-17 WO PCT/EP2017/070850 patent/WO2018033598A1/en not_active Ceased
- 2017-08-17 EA EA201990514A patent/EA201990514A1/ru unknown
- 2017-08-17 PL PL17758473.7T patent/PL3500241T3/pl unknown
- 2017-08-17 SG SG11201900471VA patent/SG11201900471VA/en unknown
-
2019
- 2019-01-14 ZA ZA2019/00239A patent/ZA201900239B/en unknown
- 2019-02-03 IL IL264612A patent/IL264612B2/en unknown
- 2019-02-14 PH PH12019500315A patent/PH12019500315A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500315A1 (en) | Combination therapy for copd | |
| CY1123810T1 (el) | Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
| CY1123391T1 (el) | (2s)-n-[(1s)-1-kyano-2-φainyλaιθyλ]-1,4-oξazeπan-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης ι | |
| CY1124407T1 (el) | Ενωσεις αναστολεα αυτοταξινης | |
| IL289975A (en) | Use of cannabidiol in the treatment of dravet syndrome | |
| NO2025052I1 (no) | a combination of (a) vanzacaftor or a pharmaceutically acceptable salt thereof, preferably a calcium salt thereof, (b) tezacaftor or a pharmaceutically acceptable salt thereof, and (c) deutivacaftor or a pharmaceutically acceptable salt thereof | |
| CY1124652T1 (el) | Παραγωγα 1η-ινδαζολο-3-καρβοξαμιδιου και σχετικες ενωσεις ως αναστολεις παραγοντα d για τη θεραπεια νοσων που χαρακτηριζονται απο μη φυσιολογικη δραστηριοτητα συστηματος συμπληρωματος, οπως π.χ. ανοσολογικες διαταραχες | |
| CY1124432T1 (el) | Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη | |
| PT3883579T (pt) | Terapia de combinação incluindo um inibidor de kras-g12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cancros | |
| CY1120903T1 (el) | Ενωσεις αμινοπυριδυλοξυπυραζολιου | |
| MX387115B (es) | Métodos para tratar la influenza. | |
| SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
| CY1124907T1 (el) | Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
| MX374537B (es) | Tricíclicos sustituidos y método para usarlos. | |
| MX383499B (es) | Agentes terapeuticos para enfermedades neurodegenerativas | |
| DK3328843T3 (da) | 1,3,4-oxadiazolsulfonamidderivat-forbindelser som histon- deacetylase-6-inhibitor, og den farmaceutske sammensætning | |
| MX387720B (es) | Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de conductancia de transmembrana de fibrosis quística. | |
| CR20160538A (es) | Combinación | |
| CN107406464A8 (zh) | 精氨酸酶抑制剂及其治疗用途 | |
| MX382765B (es) | Tratamiento para la colangitis biliar primaria. | |
| LT3890767T (lt) | Inhaliuojamos kompozicijos, skirtos naudoti plaučių ligų gydymui | |
| MX2016002302A (es) | Composiciones y metodos terapeuticos para la regresion acelerada de placa. | |
| LT3268374T (lt) | Kv1.3 inhibitoriai ir jų medicininis pritaikymas | |
| DK3302543T3 (da) | Vaccinesammensætninger mod porcint reproduktions- og respirationssyndrom og porcint circovirus-associerede sygdomme | |
| PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same |